UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The role of PARP in DNA repair and its therapeutic exploitation

British journal of cancer, 2011-10, Vol.105 (8), p.1114-1122

2011

Volltextzugriff (PDF)

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

British journal of cancer, 2011-07, Vol.105 (3), p.372-381

2011

Volltextzugriff (PDF)

Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells

British journal of cancer, 2024-09, Vol.131 (5), p.955-955

2024

Volltextzugriff (PDF)

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase

British journal of cancer, 2014-09, Vol.111 (7), p.1319-1326

2014

Volltextzugriff (PDF)

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy

Therapeutic Advances in Medical Oncology, 2011-11, Vol.3 (6), p.257-267

2011

Volltextzugriff (PDF)

Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer

British journal of pharmacology, 2013-08, Vol.169 (8), p.1745-1765

Curtin, N J

2013

Volltextzugriff (PDF)

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules

British journal of cancer, 2014-04, Vol.110 (8), p.1977-1984

2014

Volltextzugriff (PDF)

Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples

British journal of cancer, 2014-05, Vol.111 (1), p.94-100

2014

Volltextzugriff (PDF)

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699

British journal of cancer, 2010-11, Vol.103 (10), p.1588-1596

2010

Volltextzugriff (PDF)

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

British journal of cancer, 2001-01, Vol.84 (1), p.106-112

2001

Volltextzugriff (PDF)

Resistance-Modifying Agents. 9. Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase

Journal of medicinal chemistry, 2000-11, Vol.43 (22), p.4084-4097

2000

Volltextzugriff (PDF)

Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer

Oncogene, 2007-12, Vol.26 (55), p.7611-7619

2007

Volltextzugriff (PDF)

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer

British journal of radiology, 2008-10, Vol.81 Spec No 1 (special_issue_1), p.S6-S11

2008

Volltextzugriff (PDF)

Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles

Journal of medicinal chemistry, 2000-07, Vol.43 (15), p.2797-2804

2000

Volltextzugriff (PDF)

Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design

Breast (Edinburgh), 2012-02, Vol.21 (1), p.20-26

2012

Volltextzugriff (PDF)

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064

British journal of cancer, 1998-11, Vol.78 (10), p.1269-1277

1998

Volltextzugriff (PDF)

Potentiation of Temozolomide and Topotecan Growth Inhibition and Cytotoxicity by Novel Poly(adenosine Diphosphoribose) Polymerase Inhibitors in a Panel of Human Tumor Cell Lines

Clinical cancer research, 2000-07, Vol.6 (7), p.2860-2867

2000

Volltextzugriff (PDF)

Defective homologous recombination in human cancers

Cancer treatment reviews, 2012-04, Vol.38 (2), p.89-100

2012

Volltextzugriff (PDF)

Pemetrexed disodium, a novel antifolate with multiple targets

The lancet oncology, 2001-05, Vol.2 (5), p.298-306

2001

Volltextzugriff (PDF)

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

British journal of cancer, 2009-07, Vol.101 (2), p.256-262

2009

Volltextzugriff (PDF)

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells

British journal of cancer, 2010-01, Vol.102 (2), p.342-350

2010

Volltextzugriff (PDF)

Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1

Cancer research (Chicago, Ill.), 2003-09, Vol.63 (18), p.6008-6015

2003

Volltextzugriff (PDF)

Resistance-Modifying Agents. 5. Synthesis and Biological Properties of Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP)

Journal of medicinal chemistry, 1998-12, Vol.41 (26), p.5247-5256

1998

Volltextzugriff (PDF)

The Impact of p53 Status on Cellular Sensitivity to Antifolate Drugs

Clinical cancer research, 2001-07, Vol.7 (7), p.2114-2123

2001

Volltextzugriff (PDF)

The Philadelphia translocation and pre‐existing myeloproliferative disorders

British journal of haematology, 2005-03, Vol.128 (5), p.734-736

2005

Volltextzugriff (PDF)

1 – 25 von 495

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(443)
Mit Volltextzugriff
(388)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

The role of PARP in DNA repair and its therapeutic exploitation

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy

Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules

Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

Resistance-Modifying Agents. 9. Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase

Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer

Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles

Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064

Potentiation of Temozolomide and Topotecan Growth Inhibition and Cytotoxicity by Novel Poly(adenosine Diphosphoribose) Polymerase Inhibitors in a Panel of Human Tumor Cell Lines

Defective homologous recombination in human cancers

Pemetrexed disodium, a novel antifolate with multiple targets

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells

Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1

Resistance-Modifying Agents. 5. Synthesis and Biological Properties of Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP)

The Impact of p53 Status on Cellular Sensitivity to Antifolate Drugs

The Philadelphia translocation and pre‐existing myeloproliferative disorders

Suchergebnisse filtern